BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 12019170)

  • 1. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
    Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
    Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
    Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
    Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer.
    Brambilla E; Gazzeri S; Lantuejoul S; Coll JL; Moro D; Negoescu A; Brambilla C
    Clin Cancer Res; 1998 Jul; 4(7):1609-18. PubMed ID: 9676834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
    Ralhan R; Agarwal S; Mathur M; Wasylyk B; Srivastava A
    Clin Cancer Res; 2000 Jun; 6(6):2440-7. PubMed ID: 10873097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From astrocytoma to glioblastoma: a clonal evolution study.
    Yang F; Zou Y; Gong Q; Chen J; Li WD; Huang Q
    FEBS Open Bio; 2020 May; 10(5):744-751. PubMed ID: 32069381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells.
    Harwood FG; Frazier MW; Krajewski S; Reed JC; Houghton JA
    Oncogene; 1996 May; 12(10):2057-67. PubMed ID: 8668331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
    Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
    Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
    Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
    Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
    Park US; Park SK; Lee YI; Park JG; Lee YI
    Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
    Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
    Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.